SBUR Spring Meeting at AUA2019
Saturday, May 4
**SBUR/SUO Joint Morning Session Education Needs & Objectives**

**Educational Needs**
Pathophysiology of the GU tract is complex. Treatment of GU malignancies has relied heavily on a single type of treatment administered at one time, followed by other modalities depending on treatment success. However, there is reason to believe multimodality therapy would have increased likelihood of efficacy. The goal of the meeting on is to address knowledge gaps and discuss the benefits and limitations of multimodality therapy for prostate, bladder and renal cancers.

**Educational Objectives**
At the conclusion of the SBUR/SUO Morning Meeting, participants will be able to:
- Recognize the best multimodality systemic therapy advances for metastatic hormone-resistant prostate cancer.
- Explain the concept of oligometastatic treatment.
- Describe therapeutic advances in BCG-unresponsive non-muscle-invasive bladder cancer, including immune- based therapy, enhanced delivery systems and combination chemo-immune therapy.
- Discuss the best systemic therapy advances in metastatic kidney cancer.
- Describe the role of radical nephrectomy in the post-tyrosine kinase inhibitor era in renal cancer.

**SBUR Afternoon Breakout Sessions Education Needs & Objectives**

**Educational Needs**
It is increasingly apparent that health states and manifestation of diseases throughout the body, including the genitourinary tract, are greatly influenced by both non-modifiable factors such as biological sex and potentially modifiable factors such as the microbiome. To best treat patients with diseases of the genitourinary system, it is essential to fill gaps in our knowledge regarding the impact of sex differences and microbes on urologic health and disease. It is anticipated that increased understanding of these factors will enable improved treatment of patients with both benign and malignant GU diseases.

**Educational Objectives**
At the conclusion of the SBUR Afternoon Breakout Sessions, participants will be able to:
- Describe the impact of biological sex on manifestation of various lower urinary tract disorders including voiding dysfunction, infection and cancer.
- Explain the influence of resident microbes on urinary tract function and dysfunction, and the response to therapeutic intervention.
Society for Basic Urologic Research and Society of Urologic Oncology (SBUR/SUO)

2019 AUA Accreditation Information

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
Society for Basic Urologic Research (SBUR)

2019 AUA Accreditation Information

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.
## Society for Basic Urologic Research & Society of Urologic Oncology

### Joint Morning Session Schedule

7:55–11:50am | McCormick Place Convention Center West Building Room W196

### Welcome and Introduction
- **Moderator**: Rosalyn Adam, PhD; SBUR Vice President and Spring Program Chair; Michael S. Cookson, MD, MMHC, SUO President-Elect and Spring Program Chair

### 8:00–9:00am  
**Metastatic Prostate Cancer**

- **Moderator**: Daniel Lin, MD
- **8:00–8:05am**
  - **Basic Science Perspective**: The Big Picture for Mechanisms of Resistance in Prostate Cancer — Nima Sharifi, MD
- **8:05–8:20am**
  - **Clinical Perspective**: The Evolving Therapeutics of Advanced Prostate Cancer — "It's A New World Order" — Maha Hussain, MD, FACP
- **8:20–8:35am**
  - **Panel Discussion** — Nima Sharifi, MD; Maha Hussain, MD, FACP; Edouard Trabulsi, MD, FACS; Mark Garzotto, MD

### 9:00–10:00am  
**BCG Unresponsive Non-Muscle Invasive Bladder**

- **Moderator**: James McKiernan, MD
- **9:00–9:05am**
  - **Basic Science Perspective**: Budding Biotechnologies for Bladder Cancer — Brant Inman, MD, MS, FRCSC
- **9:05–9:20am**
  - **Clinical Perspective**: BCG Unresponsive Non-Muscle Invasive Bladder Cancer — Stephen A. Boorjian, MD
- **9:20–9:35am**
  - **Panel Discussion** — Brant Inman, MD, MS; Stephen A. Boorjian, MD; Peter Clark, MD; Matthew Nielsen, MD, MS

### 10:00–10:50am  
**Metastatic Kidney Cancer**

- **Moderator**: Steve Campbell, MD, PhD
- **10:00–10:05am**
  - **Basic Science Perspective**: Basic/Translational Aspects Underlying Cytoreductive Nephrectomy and Integration of Surgery/Systemic Therapies — Walter Stadler, MD
- **10:05–10:20am**
  - **Clinical Perspective**: Clinical and Surgical Perspectives on Cytoreductive Nephrectomy — Robert Uzzo, MD
- **10:20–10:35am**
  - **Panel Discussion** — Walter Stadler, MD; Robert Uzzo, MD; Surena Matin, MD

### 10:55–11:50am  
**Donald S. Coffey Lecture: Breast Tumor Heterogeneity**

- **Introduction**: Rosalyn Adam, PhD
- **10:55–11:00am**
  - **Donald S. Coffey Lecture**: Breast Tumor Heterogeneity — Kornelia Polyak, MD, PhD, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
  
  Kornelia Polyak MD, PhD is a Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and is an internationally recognized leader of the breast cancer field. Dr. Polyak received her MD in 1991 from Albert Szent-Gyorgyi Medical University, Szeged, Hungary, and her PhD in 1995 from Cornell University/Memorial Sloan-Kettering Cancer Center. She completed a research fellowship in oncology at the Johns Hopkins Oncology Center, Baltimore, where she analyzed the mechanism of p53-mediated cell death. Joining DFCI in 1998, she is principally involved in basic laboratory research focusing on cancer genetics and the molecular basis of breast cancer.

- **11:00–11:40am**
  - **Q & A**
12–1pm | SBUR Member Luncheon
McCormick Place Convention Center West Building Room W193A

Society for Basic Urologic Research
Afternoon Breakout Session Schedule
1:00–4:00pm | McCormick Place Convention Center West Building Room W193B

1:00–1:05pm
Welcome and Introduction
— Rosalyn Adam, PhD, SBUR Vice President and Spring Program Chair

1:05–2:30pm
Session I: Sex Differences in Urologic Health and Disease

1:05–1:20pm
Sex, Epigenetics and Bladder Cancer — Sean Li, PhD

1:20–1:35pm
Androgen Receptors in Kidney Tumors and Kidney Stones — Chawnshang Chang, PhD

1:35–1:50pm
Sexual Dimorphisms in Neurourology — Stephen Zderic, MD

1:50–2:05pm
Sex Differences in Urologic Chronic Pelvic Pain Syndrome — Jennifer Anger, MD, MPH

2:05–2:25pm
Panel Discussion — Moderators: Rosalyn Adam, PhD; Laura Lamb, PhD

2:30–4:00pm
Session II: Microbes and the Urinary Tract

2:35–2:50pm
Urine is Not Sterile: What’s Next? — Alan Wolfe, PhD

2:50–3:05pm
The Genitourinary Microbiome, Inflammation, and Prostate Disease — Karen Sfanos, PhD

3:05–3:20pm
The Unexpected Role of the Urinary Microbiome in Bladder Cancer Immunotherapy Efficacy — Randy Sweis, MD

3:20–3:35pm
The Impact of Microbial Immune Modulation on Prostate Disease — Praveen Thumbikat, DVM, PhD

3:35–4:00pm
Panel Discussion — Moderators: Magdalena Grabowska, PhD; Leigh Ellis, PhD